Circulating levels of endotrophin and cross-linked type III collagen reflect liver fibrosis in people with HIV.
Humans
Biomarkers
/ blood
Collagen Type III
/ blood
Collagen Type VI
/ blood
Fatty Liver
/ blood
HIV Infections
/ blood
Liver
/ diagnostic imaging
Liver Cirrhosis
/ blood
Retrospective Studies
Extracellular Matrix
/ metabolism
Antiretroviral Therapy, Highly Active
Collagen Type V
/ blood
Procollagen
/ blood
Endotrophin
HIV
Hepatic steatosis
Liver fibrosis
PC3X
PRO-C5
PRO-C6
Journal
BMC infectious diseases
ISSN: 1471-2334
Titre abrégé: BMC Infect Dis
Pays: England
ID NLM: 100968551
Informations de publication
Date de publication:
24 Jan 2023
24 Jan 2023
Historique:
received:
11
03
2022
accepted:
10
01
2023
entrez:
24
1
2023
pubmed:
25
1
2023
medline:
27
1
2023
Statut:
epublish
Résumé
Liver-associated complications still frequently lead to mortality in people with HIV (PWH), even though combined antiretroviral treatment (cART) has significantly improved overall survival. The quantification of circulating collagen fragments released during collagen formation and degradation correlate with the turnover of extracellular matrix (ECM) in liver disease. Here, we analysed the levels of ECM turnover markers PC3X, PRO-C5, and PRO-C6 in PWH and correlated these with hepatic fibrosis and steatosis. This monocentre, retrospective study included 141 PWH. Liver stiffness and liver fat content were determined using transient elastography (Fibroscan) with integrated CAP function. Serum levels of formation of cross-linked type III collagen (PC3X), formation of type V collagen (PRO-C5) and formation type VI collagen (PRO-C6), also known as the hormone endotrophin, were measured with ELISA. Twenty-five (17.7%) of 141 PWH had clinical significant fibrosis with liver stiffness ≥ 7.1 kPa, and 62 PWH (44.0%) had steatosis with a CAP value > 238 dB/m. Study participants with fibrosis were older (p = 0.004) and had higher levels of AST (p = 0.037) and lower number of thrombocytes compared to individuals without fibrosis (p = 0.0001). PC3X and PRO-C6 were markedly elevated in PWH with fibrosis. Multivariable cox regression analysis confirmed PC3X as independently associated with hepatic fibrosis. PRO-C5 was significantly elevated in participants with presence of hepatic steatosis. Serological levels of cross-linked type III collagen formation and endotrophin were significantly associated with liver fibrosis in PWH receiving cART and thus may be suitable as a non-invasive evaluation of liver fibrosis in HIV disease.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Liver-associated complications still frequently lead to mortality in people with HIV (PWH), even though combined antiretroviral treatment (cART) has significantly improved overall survival. The quantification of circulating collagen fragments released during collagen formation and degradation correlate with the turnover of extracellular matrix (ECM) in liver disease. Here, we analysed the levels of ECM turnover markers PC3X, PRO-C5, and PRO-C6 in PWH and correlated these with hepatic fibrosis and steatosis.
METHODS
METHODS
This monocentre, retrospective study included 141 PWH. Liver stiffness and liver fat content were determined using transient elastography (Fibroscan) with integrated CAP function. Serum levels of formation of cross-linked type III collagen (PC3X), formation of type V collagen (PRO-C5) and formation type VI collagen (PRO-C6), also known as the hormone endotrophin, were measured with ELISA.
RESULTS
RESULTS
Twenty-five (17.7%) of 141 PWH had clinical significant fibrosis with liver stiffness ≥ 7.1 kPa, and 62 PWH (44.0%) had steatosis with a CAP value > 238 dB/m. Study participants with fibrosis were older (p = 0.004) and had higher levels of AST (p = 0.037) and lower number of thrombocytes compared to individuals without fibrosis (p = 0.0001). PC3X and PRO-C6 were markedly elevated in PWH with fibrosis. Multivariable cox regression analysis confirmed PC3X as independently associated with hepatic fibrosis. PRO-C5 was significantly elevated in participants with presence of hepatic steatosis.
CONCLUSION
CONCLUSIONS
Serological levels of cross-linked type III collagen formation and endotrophin were significantly associated with liver fibrosis in PWH receiving cART and thus may be suitable as a non-invasive evaluation of liver fibrosis in HIV disease.
Identifiants
pubmed: 36694115
doi: 10.1186/s12879-023-08000-w
pii: 10.1186/s12879-023-08000-w
pmc: PMC9872428
doi:
Substances chimiques
Biomarkers
0
Collagen Type III
0
Collagen Type VI
0
endotrophin
0
Collagen Type V
0
Procollagen
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
52Informations de copyright
© 2023. The Author(s).
Références
Medicine (Baltimore). 2018 Apr;97(17):e0462
pubmed: 29702998
Scand J Gastroenterol. 2015 May;50(5):584-92
pubmed: 25639675
Clin Gastroenterol Hepatol. 2010 Feb;8(2):183-91
pubmed: 19800985
AIDS. 2010 Jun 19;24(10):1537-48
pubmed: 20453631
Sci Rep. 2018 Aug 17;8(1):12414
pubmed: 30120271
Clin Res Hepatol Gastroenterol. 2012 Feb;36(1):13-20
pubmed: 21920839
Biomark Insights. 2011 Mar 24;6:49-58
pubmed: 21499440
EClinicalMedicine. 2021 Sep 05;40:101116
pubmed: 34522873
Cells. 2021 May 15;10(5):
pubmed: 34063534
Anesth Analg. 2003 May;96(5):1392-1396
pubmed: 12707140
Am J Physiol Gastrointest Liver Physiol. 2019 Jan 1;316(1):G25-G31
pubmed: 30160980
Clin Infect Dis. 2011 Mar 1;52(5):674-80
pubmed: 21248367
J Viral Hepat. 2003 Mar;10(2):118-25
pubmed: 12614468
Nat Commun. 2014 Mar 19;5:3485
pubmed: 24647224
Gastroenterology. 2005 Feb;128(2):343-50
pubmed: 15685546
J Hepatocell Carcinoma. 2020 Nov 09;7:301-313
pubmed: 33204663
Liver Int. 2012 Jul;32(6):902-10
pubmed: 22435761
J Hepatol. 2010 Dec;53(6):1013-21
pubmed: 20850886
AIDS. 2014 Sep 10;28(14):2081-90
pubmed: 25136933
Lancet. 2003 Nov 22;362(9397):1708-13
pubmed: 14643119
J Viral Hepat. 2007 Mar;14(3):183-8
pubmed: 17305884
Oxid Med Cell Longev. 2016;2016:8910396
pubmed: 27829986
PLoS One. 2019 Jul 11;14(7):e0219526
pubmed: 31295293
Curr HIV/AIDS Rep. 2016 Aug;13(4):218-25
pubmed: 27245605
Aliment Pharmacol Ther. 2018 Jul;48(2):179-189
pubmed: 29851098
Lancet. 2011 Apr 2;377(9772):1198-209
pubmed: 21459211
Hepat Oncol. 2020 Dec 18;8(2):HEP32
pubmed: 34084451
PLoS One. 2014 Mar 17;9(3):e91987
pubmed: 24637477
J Hepatol. 2021 Sep;75(3):659-689
pubmed: 34166721
J Neurovirol. 2014 Feb;20(1):39-53
pubmed: 24420448
Clin Microbiol Rev. 2013 Jan;26(1):2-18
pubmed: 23297256
Biomarkers. 2011 Nov;16(7):616-28
pubmed: 21988680
PLoS One. 2015 Dec 07;10(12):e0144525
pubmed: 26641456
Front Physiol. 2013 Jul 30;4:195
pubmed: 23908632
Swiss Med Wkly. 2019 Apr 26;149:w20077
pubmed: 31026041
Aliment Pharmacol Ther. 2013 Nov;38(9):1086-96
pubmed: 24099470
J Viral Hepat. 2017 May;24(5):412-420
pubmed: 27925409
J Microbiol Immunol Infect. 2016 Aug;49(4):546-53
pubmed: 25440980
Hepatol Commun. 2018 Jan 18;2(2):211-222
pubmed: 29404528